BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 25046141)

  • 1. The metastatic microenvironment: Claudin-1 suppresses the malignant phenotype of melanoma brain metastasis.
    Izraely S; Sagi-Assif O; Klein A; Meshel T; Ben-Menachem S; Zaritsky A; Ehrlich M; Prieto VG; Bar-Eli M; Pirker C; Berger W; Nahmias C; Couraud PO; Hoon DS; Witz IP
    Int J Cancer; 2015 Mar; 136(6):1296-307. PubMed ID: 25046141
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The metastatic microenvironment: brain-residing melanoma metastasis and dormant micrometastasis.
    Izraely S; Sagi-Assif O; Klein A; Meshel T; Tsarfaty G; Pasmanik-Chor M; Nahmias C; Couraud PO; Ateh E; Bryant JL; Hoon DS; Witz IP
    Int J Cancer; 2012 Sep; 131(5):1071-82. PubMed ID: 22025079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The metastatic microenvironment: Brain-derived soluble factors alter the malignant phenotype of cutaneous and brain-metastasizing melanoma cells.
    Klein A; Sagi-Assif O; Izraely S; Meshel T; Pasmanik-Chor M; Nahmias C; Couraud PO; Erez N; Hoon DS; Witz IP
    Int J Cancer; 2012 Dec; 131(11):2509-18. PubMed ID: 22447293
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The melanoma brain metastatic microenvironment: aldolase C partakes in shaping the malignant phenotype of melanoma cells - a case of inter-tumor heterogeneity.
    Izraely S; Ben-Menachem S; Sagi-Assif O; Meshel T; Malka S; Telerman A; Bustos MA; Ramos RI; Pasmanik-Chor M; Hoon DSB; Witz IP
    Mol Oncol; 2021 May; 15(5):1376-1390. PubMed ID: 33274599
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNA methylation maintains the CLDN1-EPHB6-SLUG axis to enhance chemotherapeutic efficacy and inhibit lung cancer progression.
    Wu JE; Wu YY; Tung CH; Tsai YT; Chen HY; Chen YL; Hong TM
    Theranostics; 2020; 10(19):8903-8923. PubMed ID: 32754286
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Claudin-1 is a metastasis suppressor and correlates with clinical outcome in lung adenocarcinoma.
    Chao YC; Pan SH; Yang SC; Yu SL; Che TF; Lin CW; Tsai MS; Chang GC; Wu CH; Wu YY; Lee YC; Hong TM; Yang PC
    Am J Respir Crit Care Med; 2009 Jan; 179(2):123-33. PubMed ID: 18787218
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The metastatic microenvironment: Melanoma-microglia cross-talk promotes the malignant phenotype of melanoma cells.
    Izraely S; Ben-Menachem S; Sagi-Assif O; Telerman A; Zubrilov I; Ashkenazi O; Meshel T; Maman S; Orozco JIJ; Salomon MP; Marzese DM; Pasmanik-Chor M; Pikarski E; Ehrlich M; Hoon DSB; Witz IP
    Int J Cancer; 2019 Feb; 144(4):802-817. PubMed ID: 29992556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A new Mr 55,000 surface protein implicated in melanoma progression: association with a metastatic phenotype.
    Boukerche H; Baril P; Tabone E; Bérard F; Sanhadji K; Balme B; Wolf F; Perrot H; Thomas L
    Cancer Res; 2000 Oct; 60(20):5848-56. PubMed ID: 11059782
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Claudin-1 overexpression in melanoma is regulated by PKC and contributes to melanoma cell motility.
    Leotlela PD; Wade MS; Duray PH; Rhode MJ; Brown HF; Rosenthal DT; Dissanayake SK; Earley R; Indig FE; Nickoloff BJ; Taub DD; Kallioniemi OP; Meltzer P; Morin PJ; Weeraratna AT
    Oncogene; 2007 May; 26(26):3846-56. PubMed ID: 17160014
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Challenge of Classifying Metastatic Cell Properties by Molecular Profiling Exemplified with Cutaneous Melanoma Cells and Their Cerebral Metastasis from Patient Derived Mouse Xenografts.
    Neuditschko B; Janker L; Niederstaetter L; Brunmair J; Krivanek K; Izraely S; Sagi-Assif O; Meshel T; Keppler BK; Del Favero G; Witz IP; Gerner C
    Mol Cell Proteomics; 2020 Mar; 19(3):478-489. PubMed ID: 31892524
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Claudin-1 enhances tumor proliferation and metastasis by regulating cell anoikis in gastric cancer.
    Huang J; Zhang L; He C; Qu Y; Li J; Zhang J; Du T; Chen X; Yu Y; Liu B; Zhu Z
    Oncotarget; 2015 Jan; 6(3):1652-65. PubMed ID: 25544763
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of HCC with claudin-1-specific antibodies suppresses carcinogenic signaling and reprograms the tumor microenvironment.
    Roehlen N; Muller M; Nehme Z; Crouchet E; Jühling F; Del Zompo F; Cherradi S; Duong FHT; Almeida N; Saviano A; Fernández-Vaquero M; Riedl T; El Saghire H; Durand SC; Ponsolles C; Oudot MA; Martin R; Brignon N; Felli E; Pessaux P; Lallement A; Davidson I; Bandiera S; Thumann C; Marchand P; Moll S; Nicolay B; Bardeesy N; Hoshida Y; Heikenwälder M; Iacone R; Toso A; Meyer M; Elson G; Schweighoffer T; Teixeira G; Zeisel MB; Laquerriere P; Lupberger J; Schuster C; Mailly L; Baumert TF
    J Hepatol; 2023 Feb; 78(2):343-355. PubMed ID: 36309131
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Malignant potential of cells isolated from lymph node or brain metastases of melanoma patients and implications for prognosis.
    Zhang RD; Price JE; Schackert G; Itoh K; Fidler IJ
    Cancer Res; 1991 Apr; 51(8):2029-35. PubMed ID: 1826230
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of a preclinical model of spontaneous human melanoma central nervous system metastasis.
    Cruz-Munoz W; Man S; Xu P; Kerbel RS
    Cancer Res; 2008 Jun; 68(12):4500-5. PubMed ID: 18559492
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibody targeting of claudin-1 as a potential colorectal cancer therapy.
    Cherradi S; Ayrolles-Torro A; Vezzo-Vié N; Gueguinou N; Denis V; Combes E; Boissière F; Busson M; Canterel-Thouennon L; Mollevi C; Pugnière M; Bibeau F; Ychou M; Martineau P; Gongora C; Del Rio M
    J Exp Clin Cancer Res; 2017 Jun; 36(1):89. PubMed ID: 28659146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation of stat3 in human melanoma promotes brain metastasis.
    Xie TX; Huang FJ; Aldape KD; Kang SH; Liu M; Gershenwald JE; Xie K; Sawaya R; Huang S
    Cancer Res; 2006 Mar; 66(6):3188-96. PubMed ID: 16540670
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Loss of claudin-1 expression in tumor-associated vessels correlates with acquisition of metastatic phenotype in melanocytic neoplasms.
    Cohn ML; Goncharuk VN; Diwan AH; Zhang PS; Shen SS; Prieto VG
    J Cutan Pathol; 2005 Sep; 32(8):533-6. PubMed ID: 16115050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vemurafenib resistance selects for highly malignant brain and lung-metastasizing melanoma cells.
    Zubrilov I; Sagi-Assif O; Izraely S; Meshel T; Ben-Menahem S; Ginat R; Pasmanik-Chor M; Nahmias C; Couraud PO; Hoon DS; Witz IP
    Cancer Lett; 2015 May; 361(1):86-96. PubMed ID: 25725450
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CCR4 is a determinant of melanoma brain metastasis.
    Klein A; Sagi-Assif O; Meshel T; Telerman A; Izraely S; Ben-Menachem S; Bayry J; Marzese DM; Ohe S; Hoon DSB; Erez N; Witz IP
    Oncotarget; 2017 May; 8(19):31079-31091. PubMed ID: 28415693
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MicroRNA-155 is a novel suppressor of ovarian cancer-initiating cells that targets CLDN1.
    Qin W; Ren Q; Liu T; Huang Y; Wang J
    FEBS Lett; 2013 May; 587(9):1434-9. PubMed ID: 23523916
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.